8 May 2014 - Deborah Wilkes
Bayer has agreed to acquire US-based Merck & Co's Consumer Care business for US$14.2 billion, and has big plans for the brands outside the US.
The German company describes the journey towards the deal, which was announced on 6 May 2014, as a "highly-contested quest for a crown jewel". In addition to making Bayer Consumer Care the world's second largest OTC player, the deal will take the business into the OTC allergy remedy category and almost double the size of its North American sales.
This NEWS EXTRA publication from OTCToolbox is designed to give you a rapid and detailed insight into the OTC deal. Make sure your team is well informed through a Multiple User Licence or a Global Licence.
The publication covers Bayer's growth strategy in consumer healthcare and the company's recent OTC acquisitions in Germany and China, as well as plans for its expanded Consumer Care business once Merck & Co's OTC brands are on board. Bayer aims to achieve revenue synergies of around US$400 million by 2017.
Around 3,000 words long, this NEWS EXTRA publication from OTCToolbox is written by OTC industry expert Deborah Wilkes. It is available to purchase and download immediately from the OTCToolbox website.
RAPID INSIGHTS MADE EASY
AVAILABLE TO DOWNLOAD IMMEDIATELY AS A PDF
See Payment Options box on this page
This NEWS EXTRA is also available as part of an Annual Subscription to the OTCToolbox website (click here to find out more).
For alternative payment options and delivery methods, or other questions, please send an email to email@example.com